[Role of protein kinases of human red cell membrane in deformability and aggregation changes].
The proteomic analysis has showed that red cell membrane contains several kinases and phosphatases. Therefore the aim of this study was to investigate the role of protein kinases of human red cell membrane in deformability and aggregation changes. Exposure of red blood cells (RBCs) to some chemical compounds led to change in the RBC microrheological properties. When forskolin (10 microM), an adenylyl cyclase (AC) and a protein kinase A (PKA) stimulator was added to RBC suspension, the RBC deformability (RBCD) was increased by 20% (p < 0.05). Somewhat more significant deformability rise appeared after RBC incubation with dB-AMP (by 26%; p < 0.01). Red cell aggregation (RBCA) was significantly decreased under these conditions (p < 0.01). Markedly less changes of deformability was found after RBC incubation with protein kinase stimulator C (PKC)--phorbol 12-myristate 13-acetate (PMA). This drug reduced red cell aggregation only slightly. It was inhibited red cell tyrosine phosphotase activity by N-vanadat and was obtained a significant RBCD rise and RBCA lowering. The similar effect was found when cells were incubated with cisplatin as a tyrosine protein kinase (TPK) activator. It is important to note that a selective TPK inhibitor--lavendustin eliminated the above mention effects. On the whole the total data clearly show that the red cell aggregation and deformation changes were connected with an activation of the different intracellular signaling pathways.
A V
AV
Murav'ev
A A
AA
Maĭmistova
I A
IA
Tikhomirova
S V
SV
Bulaeva
P V
PV
Mikhaĭlov
A A
AA
Murav'ev
D000262:Adenylyl Cyclases / Q000494:pharmacology; D002449:Cell Aggregation / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology*; D002945:Cisplatin / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism / Q000502:physiology*; D004789:Enzyme Activation / Q000502:physiology; D004907:Erythrocyte Deformability / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D017027:Protein Tyrosine Phosphatases / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014638:Vanadates / Q000494:pharmacology
D005576:Colforsin; D014638:Vanadates; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D017027:Protein Tyrosine Phosphatases; D000262:Adenylyl Cyclases; D013755:Tetradecanoylphorbol Acetate; D002945:Cisplatin